GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shine-On BioMedical Co Ltd (ROCO:6926) » Definitions » Net Income From Continuing Operations

Shine-On BioMedical Co (ROCO:6926) Net Income From Continuing Operations : NT$-118.59 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Shine-On BioMedical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Shine-On BioMedical Co's net income from continuing operations for the six months ended in Dec. 2024 was NT$-72.26 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2024 was NT$-118.59 Mil.

Shine-On BioMedical Co Net Income From Continuing Operations Historical Data

The historical data trend for Shine-On BioMedical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shine-On BioMedical Co Net Income From Continuing Operations Chart

Shine-On BioMedical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Income From Continuing Operations
Get a 7-Day Free Trial - -8.43 -21.82 -34.94 -118.59

Shine-On BioMedical Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Income From Continuing Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only -16.68 -11.54 -23.40 -46.34 -72.26

Shine-On BioMedical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-118.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shine-On BioMedical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shine-On BioMedical Co Ltd (ROCO:6926) » Definitions » Net Income From Continuing Operations
Comparable Companies
ROCO:4911 ROCO:6986 TPE:1733 ROCO:6492 ROCO:6864 TPE:6885 ROCO:6634 ROCO:7808 ROCO:4169 ROCO:6733 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
N/A
Address
No. 633, Section 2, Taiwan Avenue, Unit 6, 5th Floor, Xitun District, Taichung, TWN
Website
https://www.shineon-bio.com
Shine-On BioMedical Co Ltd develops drugs based on antibodies and nucleic acids. The Company researches, develops, manufactures, and distributes antibody anticancer drugs, nucleic acid anticancer drugs. The company's drug development and nucleic acid therapeutics are focused on providing patients with the most effective cancer treatment options.

Shine-On BioMedical Co Headlines

No Headlines